NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=71546&wire=1
or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: A class action securities lawsuit was filed against Amylyx Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between November 11, 2022 and November 8, 2023.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) defendants had overstated commercial prospects RELYVRIO, a dual UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the U.S.; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, defendants had also overstated RELYVRIO's prescription rate; (v) defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, defendants' public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Amylyx stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=71546&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original
press release on accesswire.com
